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KwaZulu-Natal (KZN) Province has an estimated 
39.5% HIV prevalence,[1] making it both the 
national and global epicentre of the HIV epidemic. 
As a result, multiple clinical trials are conducted 
in the region. Co-enrolment is a risk, especially 
in poorly resourced communities, and has the potential to 
jeopardise participant safety and data integrity. Proposed reasons 
for co-enrolment include incentives, altruism and added synergistic 
benefit against HIV.[2] Generally, study protocols that involve novel 
investigational products stipulate and enforce strict guidelines 
prohibiting co-enrolment.[3]
In 2008, 185 women were in violation of the exclusion criteria 
of the Centre for the AIDS Programme of Research in South 
Africa (CAPRISA) 004 and the HIV Prevention Trials Network 
(HPTN) 035 studies, both being conducted in KZN at research 
sites approximately 25 km apart. Women who co-enrolled in the 2 
studies were subsequently exited from both studies prematurely.[2] 
Reasons for co-enrolling, based on interviews, were largely attributed 
to the high-quality care and financial incentives received from 
trial participation.[4,5] In response, to prevent further co-enrolment, 
the South African (SA) Medical Research Council (MRC) HIV 
Prevention Research Unit (HPRU) developed and implemented a 
co-enrolment system using a Microsoft Access database that could be 
utilised in the CAPRISA 004 and HPTN 035 studies.
The chief limitation of the Access database was that it did not 
provide real-time updates of participant information and was not 
linked to participant personal characteristics profiles. In addition, it 
was limited to a single point of verification for co-enrolment – the 
participant’s identity document (ID) number – thus, the database was 
unable to recognise participants presenting false IDs or, in the case of 
identical twins, shared IDs. Lastly, the database was restricted to the 
MRC sites and 1 additional site.
We developed an electronic participant identification system, using 
biometric technology, to prevent co-enrolment and to ensure a 
unique and secure mechanism of identification that provided real-time 
updates. Here we report on the feasibility of this digital, fingerprint-
based method to prevent co-enrolment at multiple clinical trial sites.
Methods
We determined the availability of digital identification systems through 
consultation with research organisations and external digital information 
technology (IT) consultants. The systems presented different points of 
verification: ID number-dependent only, fingerprint-dependent only 
and ID number plus fingerprint-dependent. Upon review, we concluded 
that none of these systems satisfied our requirements. 
We conducted a ‘needs assessment’ at the 7 HPRU clinical 
research sites (CRSs) to identify criteria for the implementation of 
a biometric system. We then approached a software development 
company to develop a Biometric Co-enrolment Prevention System 
(BCEPS) according to the required specifications. A trial website 
was established; prospective BCEPS users were allowed access to 
test the system and to determine its robustness in handling different 
scenarios. 
After successful testing, we gained approval from the relevant 
regulatory authorities and, with the assistance of the MRC IT 
Department, implemented the BCEPS at the 7 HPRU CRSs in July 
2010. Information from the Access database was imported into the 
BCEPS. The BCEPS was password protected; only staff designated by 
the principal investigator (PI) were given access. Staff login was by 
fingerprint only, eliminating the sharing of usernames and passwords. 
Staff received extensive training on the use of the programme.
The BCEPS was preloaded with the names of studies and research 
sites. For fingerprint identification, the fingerprint in question 
had to be pre-loaded onto the database before a match could be 
returned. At first visit to a CRS, the participant’s name, ID number 
and fingerprints were captured onto the BCEPS, the latter using a 
fingerprint reader. At subsequent visits, each participant’s identity 
and study status was verified using their fingerprints. If the BCEPS 
showed that the participant was enrolled in another study, we 
concluded that co-enrolment was being attempted. 
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The BCEPS was designed to allow access by 
multiple CRSs and research organisations 
in different provinces. A memorandum 
of understanding (MoU) and standard 
operating procedure is signed by all 
research organisations prior to BCEPS 
implementation. 
Results
BCEPS design and implementation 
After testing of the trial website, we determined 
that the infrastructure and running costs of 
implementation would include: a computer 
and fingerprint reader of approximately 
US$2  000, an internet connection, and an 
annual fee of US$0.71 per active record for 
system maintenance. 
We implemented the BCEPS at one site at 
a time to ensure that the system functioned 
optimally. The fingerprint and profile of 
each user was required for login and needed 
to be entered into the system; this was time-
consuming, but only delayed implementation 
by a week. Staff experienced no challenges in 
learning how to use the programme. During 
the transition from the Access database to 
the BCEPS, some participants’ fingerprints 
had to be captured for the new system 
to operate optimally; consequently, it took 
approximately 3  - 4 months for the old 
database to be phased out. 
Challenges were encountered with the 
installation at some non-MRC sites: the BCEPS 
could not run on a 64-bit platform until an 
upgrade was performed; some organisations 
had to open hypertext transfer protocol secure 
(https) ports on their gateways before the 
BCEPS could be implemented and operate 
optimally. Where organisations had outsourced 
network administration, communication 
challenges between the outsourced company 
and MRC IT department required firewall 
reconfiguration. Additionally, the computers 
at some sites required upgrading to ensure 
that the ‘.NET’ framework was up to date and 
that the fingerprint reader was functional. 
Before signing the MoU, external organisations 
were advised that a new computer should be 
purchased along with the fingerprint reader. 
When there was no internet connectivity, a 
back-up system comprising a laptop loaded 
with the BCEPS and a 3G card for internet 
access was available for the HPRU sites.
Difficulties in obtaining biometrics included 
obtaining fingerprints from participants with 
dry hands (necessitating moistening of the 
hands) and from smokers with indistinct 
fingerprints; this led to numerous attempts to 
capture at least 2 digits per hand.
To date, the system has approximately 
21  728 participants on the database with 
129 798 fingerprints recorded.
Real‑time detection of co‑enrolment
Prior to BCEPS implementation, we 
preloaded all studies being conducted at 
a CRS on to the system (Fig. 1) and the 
study’s PI had to approve access to all staff 
involved. All participants presenting at a 
CRS registered their details (name, surname, 
ID number and study name); these were 
entered into the participant registration log, 
creating a digital paper trail, and thereafter 
stored by the BCEPS. Fig. 2 illustrates the 
study participation history of a participant 
enrolled in a current HIV prevention 
clinical trial. The BCEPS detected that she 
was enrolled for 2 studies. In this case, 
the respective study protocols permitted the 
participant to be co-enrolled, since one study 
was an observational one and the other a 
prevention trial. 
Participants who were found to be 
co-enrolled during the CAPRISA 004 and 
HPTN 035 clinical trials were ‘flagged’ as 
co-enrollers on the database by the MRC 
IT department at BCEPS implementation. 
When these women presented at the clinical 
Fig. 1. Screenshot of the BCEPS demonstrating how the system was preloaded with the studies conducted 
at the 7 HPRU CRSs. 
Table 1. Comparison of the co‑enrolment systems
MS Access database BCEPS
Location Site and study specific Web-based, linked across all CRSs
Access to participant data Site and study specific Linked across sites, all past and current 
studies
Quality control of participant’s information entered 
at CRSs
Unable to generate quality-control reports Daily quality-control reports generated
Database access Open to all staff Restricted fingerprint login access for 
each staff member
Point of verification for participants ID number ID number and fingerprints
Back-up system* No back-up† 3G card and laptop
MS = Microsoft; BCEPS = Biometric Co-enrolment Prevention System; CRS = clinical research sites; ID = identity document.
*Alternative system available to verify enrolment at other sites during loss of internet connectivity.
†Staff had to manually call other sites to assess if participant was enrolled there (time-consuming).
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trial sites in 2010 for participation in a new 
clinical trial, the BCEPS detected their 
co-enrolment status and confirmed their 
ineligibility for participation.
The BCEPS is monitored and quality-
controlled on a daily basis by comparing 
the CRS participant registration log with 
a BCEPS attendance report. The BCEPS 
proved comparatively more efficient than 
the Access database (Table 1) as it detected 
real-time co-enrolment; however, because 
the system is password protected to ensure 
participant confidentiality, thereby limiting 
access to designated staff only, staff were 
unable to edit any information once saved 
unless permitted by the ‘super user’.
An external evaluation of the system 
performed by an independent company 
found that the system was accurate in its 
identification of participants at CRSs, was 
user-friendly, adaptable to any research 
environment and applicable to various 
computer operating systems.
Discussion
Most women who enrol in clinical trials 
are from impoverished settlements. Thus, 
the benefits they accrue from study 
participation – including free confidential 
HIV counselling and testing, complete 
blood tests, gynaecological exams, family 
planning and referral for care to local 
hospitals – tempt them to participate 
in multiple studies, despite extensive 
counselling concerning the associated risks. 
Failure to identify co-enrolment would 
also affect the data integrity of individual 
studies. 
It is of paramount importance that 
organisations conducting clinical trials 
within the same regions implement 
a single system to prevent co-enrolment 
between research sites and studies. To our 
knowledge, there is limited global use of 
biometric technology in HIV prevention 
trials and elsewhere. In March 2012, the 
Department of Social Services launched a 
similar biometric fingerprinting system to 
curb fraud by people collecting their welfare 
grants.[6] 
The clear advantages of biometric 
identification system are that it can: 
(i)  provide extremely accurate, secured 
access to information; (ii)  perform 
automated biometric identification rapidly 
and uniformly; (iii) verify a person’s identity 
without resorting to documents that may be 
stolen, lost or altered; (iv) store information 
relating to all clinic visits and verify real-time 
enrolment of a participant at an additional 
CRS. 
We successfully tested and implemented 
the BCEPS at 7 HPRU sites and demonstrated 
that co-enrolment by participants at 
different clinical trial sites could be detected. 
Following set-up at the 7 HPRU CRSs, the 
BCEPS was established at the CAPRISA 
CRS. Having established the success of 
the system, we have subsequently been 
approached by other leading SA research 
organisations wishing to implement the 
BCEPS at their sites. The BCEPS is the first 
web-based technology to be used in SA with 
the aim of preventing co-enrolment in HIV 
prevention trials across multiple sites. 
Conclusion
The biometric verification system is a novel 
approach to prevent participant co-enrolment 
in multiple HIV prevention clinical trials. 
Our study shows that the BCEPS is able to 
prevent such co-enrolment. The key to the 
system’s success is the real-time updating of 
the participant database. The integrity of the 
system risks being compromised unless all 
research organisations, especially those in 
close proximity to each other, subscribe to a 
single biometric system such as the BCEPS. 
One major limitation is that the BCEPS is not 
presently linked to clinical trials that are being 
conducted by private organisations involving 
practitioners and pharmaceutical companies.
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Fig. 2. Screenshot of the BCEPS demonstrating the study participation history of a participant enrolled 
in an HIV prevention clinical trial. 
